COMPASS Pathways (NASDAQ:CMPS) Now Covered by Analysts at Stifel Nicolaus

Analysts at Stifel Nicolaus assumed coverage on shares of COMPASS Pathways (NASDAQ:CMPS) in a note issued to investors on Thursday,Finviz reports. The firm set a “buy” rating and a $11.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 197.30% from the stock’s previous close.

CMPS has been the subject of a number of other reports. Maxim Group reduced their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. HC Wainwright decreased their target price on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.33.

COMPASS Pathways Trading Up 1.4 %

Shares of CMPS opened at $3.70 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The firm has a market capitalization of $253.16 million, a price-to-earnings ratio of -1.68 and a beta of 2.28. The company has a 50-day moving average of $4.06 and a 200 day moving average of $5.29. COMPASS Pathways has a 1-year low of $3.16 and a 1-year high of $12.75.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently made changes to their positions in CMPS. Virtus ETF Advisers LLC lifted its position in shares of COMPASS Pathways by 21.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company’s stock valued at $61,000 after acquiring an additional 2,840 shares during the period. Conservest Capital Advisors Inc. raised its stake in COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of COMPASS Pathways by 22.8% during the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company’s stock worth $128,000 after acquiring an additional 6,297 shares in the last quarter. Barclays PLC grew its holdings in shares of COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company’s stock worth $1,585,000 after purchasing an additional 8,718 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of COMPASS Pathways by 15.4% during the 4th quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company’s stock valued at $257,000 after buying an additional 9,099 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.